{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:20:50Z","timestamp":1776144050961,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients.<\/jats:p>","DOI":"10.1038\/s41598-018-31027-y","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T11:07:37Z","timestamp":1534504057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Qi","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jugao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honggang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingduan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"31027_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrc1549","volume":"5","author":"KD Hunter","year":"2005","unstructured":"Hunter, K. D., Parkinson, E. K. & Harrison, P. R. Profiling early head and neck cancer. Nature reviews. Cancer 5, 127\u2013135, https:\/\/doi.org\/10.1038\/nrc1549 (2005).","journal-title":"Nature reviews. Cancer"},{"key":"31027_CR2","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1172\/JCI59889","volume":"122","author":"SM Rothenberg","year":"2012","unstructured":"Rothenberg, S. M. & Ellisen, L. W. The molecular pathogenesis of head and neck squamous cell carcinoma. The Journal of clinical investigation 122, 1951\u20131957 (2012).","journal-title":"The Journal of clinical investigation"},{"key":"31027_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA: a cancer journal for clinicians 65, 5\u201329, https:\/\/doi.org\/10.3322\/caac.21254 (2015).","journal-title":"CA: a cancer journal for clinicians"},{"key":"31027_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","volume":"11","author":"CR Leemans","year":"2011","unstructured":"Leemans, C. R., Braakhuis, B. J. & Brakenhoff, R. H. The molecular biology of head and neck cancer. Nature reviews. Cancer 11, 9\u201322, https:\/\/doi.org\/10.1038\/nrc2982 (2011).","journal-title":"Nature reviews. Cancer"},{"key":"31027_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.mlg.0000240182.61922.31","volume":"117","author":"AY Chen","year":"2007","unstructured":"Chen, A. Y., Schrag, N., Hao, Y., Stewart, A. & Ward, E. Changes in treatment of advanced oropharyngeal cancer, 1985-2001. The Laryngoscope 117, 16\u201321, https:\/\/doi.org\/10.1097\/01.mlg.0000240182.61922.31 (2007).","journal-title":"The Laryngoscope"},{"key":"31027_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2016.01.002","volume":"44","author":"B Gyawali","year":"2016","unstructured":"Gyawali, B., Shimokata, T., Honda, K. & Ando, Y. Chemotherapy in locally advanced head and neck squamous cell carcinoma. Cancer treatment reviews 44, 10\u201316, https:\/\/doi.org\/10.1016\/j.ctrv.2016.01.002 (2016).","journal-title":"Cancer treatment reviews"},{"key":"31027_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.radonc.2011.05.036","volume":"100","author":"P Blanchard","year":"2011","unstructured":"Blanchard, P. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 100, 33\u201340, https:\/\/doi.org\/10.1016\/j.radonc.2011.05.036 (2011).","journal-title":"Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"31027_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1017\/S0022215115002479","volume":"129","author":"B Cosway","year":"2015","unstructured":"Cosway, B., Paleri, V. & Wilson, J. Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. The Journal of laryngology and otology 129, 1046\u20131052, https:\/\/doi.org\/10.1017\/S0022215115002479 (2015).","journal-title":"The Journal of laryngology and otology"},{"key":"31027_CR9","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/sj.bjc.6690297","volume":"79","author":"MC Etienne","year":"1999","unstructured":"Etienne, M. C. et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. British journal of cancer 79, 1864\u20131869, https:\/\/doi.org\/10.1038\/sj.bjc.6690297 (1999).","journal-title":"British journal of cancer"},{"key":"31027_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejca.2004.10.014","volume":"41","author":"R Hitt","year":"2005","unstructured":"Hitt, R. et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. European journal of cancer 41, 453\u2013460, https:\/\/doi.org\/10.1016\/j.ejca.2004.10.014 (2005).","journal-title":"European journal of cancer"},{"key":"31027_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.oraloncology.2004.09.011","volume":"41","author":"X Pivot","year":"2005","unstructured":"Pivot, X. et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral oncology 41, 320\u2013327, https:\/\/doi.org\/10.1016\/j.oraloncology.2004.09.011 (2005).","journal-title":"Oral oncology"},{"key":"31027_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/annonc\/mdq588","volume":"22","author":"L Licitra","year":"2011","unstructured":"Licitra, L. et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Annals of oncology: official journal of the European Society for Medical Oncology 22, 1078\u20131087, https:\/\/doi.org\/10.1093\/annonc\/mdq588 (2011).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"31027_CR13","doi-asserted-by":"publisher","first-page":"e26399","DOI":"10.1371\/journal.pone.0026399","volume":"6","author":"Z Feng","year":"2011","unstructured":"Feng, Z. et al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PloS one 6, e26399, https:\/\/doi.org\/10.1371\/journal.pone.0026399 (2011).","journal-title":"PloS one"},{"key":"31027_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1600-0714.2011.01071.x","volume":"41","author":"C Perisanidis","year":"2012","unstructured":"Perisanidis, C. et al. Evaluation of immunohistochemical expression ofp53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 41, 40\u201346, https:\/\/doi.org\/10.1111\/j.1600-0714.2011.01071.x (2012).","journal-title":"Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology"},{"key":"31027_CR15","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England journal of medicine 351, 2817\u20132826, https:\/\/doi.org\/10.1056\/NEJMoa041588 (2004).","journal-title":"The New England journal of medicine"},{"key":"31027_CR16","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano, J. A. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine 373, 2005\u20132014, https:\/\/doi.org\/10.1056\/NEJMoa1510764 (2015).","journal-title":"The New England journal of medicine"},{"key":"31027_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJMc1515988#SA2","volume":"374","author":"T Foukakis","year":"2016","unstructured":"Foukakis, T., Falato, C. & Bergh, J. A 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine 374, 1386\u20131387, https:\/\/doi.org\/10.1056\/NEJMc1515988#SA2 (2016).","journal-title":"The New England journal of medicine"},{"key":"31027_CR18","doi-asserted-by":"publisher","first-page":"e47170","DOI":"10.1371\/journal.pone.0047170","volume":"7","author":"C Tomkiewicz","year":"2012","unstructured":"Tomkiewicz, C. et al. A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes. PloS one 7, e47170, https:\/\/doi.org\/10.1371\/journal.pone.0047170 (2012).","journal-title":"PloS one"},{"key":"31027_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/00016489.2016.1272001","volume":"137","author":"M Lian","year":"2017","unstructured":"Lian, M. et al. In vivo gene expression profiling for chemosensitivity to docetaxel-cisplatin-5-FU (TPF) triplet regimen in laryngeal squamous cell carcinoma and the effect of TPF treatment on related gene expression in vitro. Acta oto-laryngologica 137, 765\u2013772, https:\/\/doi.org\/10.1080\/00016489.2016.1272001 (2017).","journal-title":"Acta oto-laryngologica"},{"key":"31027_CR20","doi-asserted-by":"publisher","first-page":"8355","DOI":"10.18632\/oncotarget.2247","volume":"5","author":"L Roy","year":"2014","unstructured":"Roy, L. et al. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. Oncotarget 5, 8355\u20138366, https:\/\/doi.org\/10.18632\/oncotarget.2247 (2014).","journal-title":"Oncotarget"},{"key":"31027_CR21","doi-asserted-by":"publisher","first-page":"e0131961","DOI":"10.1371\/journal.pone.0131961","volume":"10","author":"A Bobbs","year":"2015","unstructured":"Bobbs, A. et al. ARID3B Directly Regulates Ovarian Cancer Promoting Genes. PloS one 10, e0131961, https:\/\/doi.org\/10.1371\/journal.pone.0131961 (2015).","journal-title":"PloS one"},{"key":"31027_CR22","doi-asserted-by":"publisher","first-page":"e0161468","DOI":"10.1371\/journal.pone.0161468","volume":"11","author":"JL Kurkewich","year":"2016","unstructured":"Kurkewich, J. L. et al. Arid3b Is Critical for B Lymphocyte Development. PloS one 11, e0161468, https:\/\/doi.org\/10.1371\/journal.pone.0161468 (2016).","journal-title":"PloS one"},{"key":"31027_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/bab.1383","volume":"63","author":"H Li","year":"2016","unstructured":"Li, H. et al. Knockdown of asparagine synthetase by RNAi suppresses cell growth in human melanoma cells and epidermoid carcinoma cells. Biotechnology and applied biochemistry 63, 328\u2013333, https:\/\/doi.org\/10.1002\/bab.1383 (2016).","journal-title":"Biotechnology and applied biochemistry"},{"key":"31027_CR24","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1007\/s13277-014-1895-z","volume":"35","author":"CY Lin","year":"2014","unstructured":"Lin, C. Y. et al. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 6823\u20136830, https:\/\/doi.org\/10.1007\/s13277-014-1895-z (2014).","journal-title":"Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"31027_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.leukres.2013.10.027","volume":"38","author":"A Pastorczak","year":"2014","unstructured":"Pastorczak, A. et al. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment. Leukemia research 38, 180\u2013183, https:\/\/doi.org\/10.1016\/j.leukres.2013.10.027 (2014).","journal-title":"Leukemia research"},{"key":"31027_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3892\/ijo.2016.3371","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil. International journal of oncology 48, 1341\u20131352, https:\/\/doi.org\/10.3892\/ijo.2016.3371 (2016).","journal-title":"International journal of oncology"},{"key":"31027_CR27","doi-asserted-by":"publisher","first-page":"43375","DOI":"10.18632\/oncotarget.6234","volume":"6","author":"L Brandolini","year":"2015","unstructured":"Brandolini, L. et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget 6, 43375\u201343394, https:\/\/doi.org\/10.18632\/oncotarget.6234 (2015).","journal-title":"Oncotarget"},{"key":"31027_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.canlet.2015.09.002","volume":"369","author":"XG Han","year":"2015","unstructured":"Han, X. G. et al. CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin. Cancer letters 369, 405\u2013415, https:\/\/doi.org\/10.1016\/j.canlet.2015.09.002 (2015).","journal-title":"Cancer letters"},{"key":"31027_CR29","first-page":"4693","volume":"34","author":"C Lohri","year":"2014","unstructured":"Lohri, C. et al. Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. Anticancer research 34, 4693\u20134699 (2014).","journal-title":"Anticancer research"},{"key":"31027_CR30","first-page":"4371","volume":"32","author":"K Hibi","year":"2012","unstructured":"Hibi, K. et al. FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer research 32, 4371\u20134374 (2012).","journal-title":"Anticancer research"},{"key":"31027_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/codi.13336","volume":"18","author":"SL Rasmussen","year":"2016","unstructured":"Rasmussen, S. L. et al. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland 18, 549\u2013561, https:\/\/doi.org\/10.1111\/codi.13336 (2016).","journal-title":"Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland"},{"key":"31027_CR32","doi-asserted-by":"publisher","unstructured":"Yang, S. et al. STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K\/AKT\/Snail signaling. Oncotarget, https:\/\/doi.org\/10.18632\/oncotarget.13355 (2016).","DOI":"10.18632\/oncotarget.13355"},{"key":"31027_CR33","doi-asserted-by":"publisher","first-page":"71400","DOI":"10.18632\/oncotarget.12147","volume":"7","author":"B Chen","year":"2016","unstructured":"Chen, B. et al. STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. Oncotarget 7, 71400\u201371416, https:\/\/doi.org\/10.18632\/oncotarget.12147 (2016).","journal-title":"Oncotarget"},{"key":"31027_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1139\/cjpp-2015-0530","volume":"94","author":"Q Yuan","year":"2016","unstructured":"Yuan, Q. et al. Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein. Canadian journal of physiology and pharmacology 94, 929\u2013935, https:\/\/doi.org\/10.1139\/cjpp-2015-0530 (2016).","journal-title":"Canadian journal of physiology and pharmacology"},{"key":"31027_CR35","doi-asserted-by":"publisher","first-page":"37297","DOI":"10.18632\/oncotarget.8934","volume":"7","author":"J Fayette","year":"2016","unstructured":"Fayette, J. et al. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget 7, 37297\u201337304, https:\/\/doi.org\/10.18632\/oncotarget.8934 (2016).","journal-title":"Oncotarget"},{"key":"31027_CR36","first-page":"6861","volume":"35","author":"M Komatsu","year":"2015","unstructured":"Komatsu, M. et al. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma. Anticancer research 35, 6861\u20136867 (2015).","journal-title":"Anticancer research"},{"key":"31027_CR37","doi-asserted-by":"publisher","unstructured":"Lian, M. et al. In vivo gene expression profiling for chemosensitivity to docetaxel-cisplatin-5-FU (TPF) triplet regimen in laryngeal squamous cell carcinoma and the effect of TPF treatment on related gene expression in vitro. Acta oto-laryngologica, 1\u201311, https:\/\/doi.org\/10.1080\/00016489.2016.1272001 (2017).","DOI":"10.1080\/00016489.2016.1272001"},{"key":"31027_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","volume":"42","author":"P Therasse","year":"2006","unstructured":"Therasse, P., Eisenhauer, E. A. & Verweij, J. RECIST revisited: a review of validation studies on tumour assessment. European journal of cancer 42, 1031\u20131039, https:\/\/doi.org\/10.1016\/j.ejca.2006.01.026 (2006).","journal-title":"European journal of cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31027-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T08:48:02Z","timestamp":1671612482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31027-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31027"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31027-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"28 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12675"}}